← Human Trials & Peer-Reviewed Studies
Case studies of three pregnant smokers and their use of nicotine replacement therapy.
Plain-language guide to PMID 15967546 (2005): randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 20 women.
Key Facts
- PMID
- 15967546
- Journal
- Midwifery
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Hotham ED et al. (3 authors)
- DOI
- 10.1016/j.midw.2004.12.008
What This Study Did, in Plain Language
What Was Tested
Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.
To examine the barriers encountered by pregnant women who attempt to stop smoking by highlighting three women who used nicotine patches.
A randomised-controlled trial of nicotine-replacement therapy (NRT) in the form of patches to test its acceptability for pregnant women.
Salivary cotinine levels were used to assess nicotine exposure and provide some indicator of NRT safety.
Why It Was Studied
40 'high-risk' pregnant smokers who expressed interest in stopping smoking.
Who Took Part
The abstract describes 20 women taking part.
By PubMed's age tags, the people studied were adults, women only.
Ethics approval was granted despite NRT being contraindicated in Australia for pregnant women and having a low safety rating (category D) (Australian Drug Evaluation Committee, 1999).
The Women's and Children's Hospital, Adelaide, a public tertiary teaching hospital in South Australia, with almost 4000 births annually.
How the Study Was Run
The design is described as randomized.
The women were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Administration, Cutaneous, Health Promotion, Maternal Behavior, Nicotine, Nicotinic Agonists, Pregnancy Complications and Pregnant People.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide) in 20 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (Midwifery), a journal based in Scotland.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.